Navigation Links
New bacteria to fight against intestinal inflammation
Date:11/6/2012

This protection is provided by a human protein, Elafin, which is artificially introduced into dairy produce bacteria (Lactococcus lactis and Lactobacillus casei). In time, this discovery could be useful for individuals suffering from chronic inflammatory diseases such as Crohn's disease or ulcerative colitis. The results of this research were published in the Science Translational Medicine review on 31 October 2012.

In France, nearly 200,000 individuals suffer from chronic inflammatory bowel disease, known as IBD, (specifically Crohn's disease and ulcerative colitis). The occurrence rate of this type of disease continues to rise (8,000 new cases diagnosed per year). During inflammatory outbreaks, IBDs are chiefly characterised by abdominal pain, frequent diarrhoea (sometimes with bleeding) or even disorders in the anal area (fissure, abscesses). These symptoms mean that taboos are associated with these diseases.

Different avenues are being explored to explain the origin of IBDs, including the role of genetic or environmental factors. The intestinal flora seems to play an important role in the outbreak of inflammation, although little is known about it. Identifying an effective treatment is also at the heart of the investigations.

Researchers are focussing on a human protein, known for its anti-inflammatory proprieties: Elafin. Although this protein is found naturally in the intestine to protect it against attacks, it disappears in patients suffering from IBDs.

Their hypothesis? Administering Elafin directly into the intestine could protect against inflammatory attacks and restore intestinal equilibrium and its functions.

Using non-pathogenic bacteria found naturally in the intestine and food, scientists from Inserm and Inra have designed modified bacteria to produce Elafin. To this end, the human Elafin gene, isolated in collaboration with a team from the Institut Pasteau, was introduced in Lactococcus lactis and Lactobacillus casei, two food-grade bacteria found in dairy products.

Results in mice

When administered orally to mice, the human Elafin-producing bacteria are found a few hours later on the surface of the intestine where they deliver the anti-inflammatory protein. In different mice models of chronic or acute intestinal inflammation, oral treatment using these Elafin-producing bacteria provided significant protection of the intestine and decreased inflammatory symptoms.

and in humans

Elafin expressed by these bacteria also protects cultured human intestinal cell lines from inflammatory outbreaks similar to those observed in chronic inflammatory bowel diseases. Elafin produced in this way restores the equilibrium of intestinal mucus by reducing inflammation and accelerating cell healing processes.

Potential clinical applications

These results may result in a clinical application where Elafin would be administered to patients suffering from IBDs using beneficial bacteria (probiotic), which are already commonly found in food (yoghurt, cheese), thus protecting the patients from inflammatory symptoms. According to the researchers "This kind of secure treatment could even be used over the long-term, to treat inflammatory diseases."


'/>"/>

Contact: Press Office
presse@inserm.fr
INSERM (Institut national de la sant et de la recherche mdicale)
Source:Eurekalert

Related medicine news :

1. Bacteria Found in Other Products From Firm Tied to Meningitis Outbreak: FDA
2. Crohns Disease in Children May Start From Bacteria
3. Scientists step up hunt for bacterial genes tied to Lyme disease
4. Oral bacteria may signal pancreatic cancer risk
5. Discovery of essential genes for drug-resistant bacteria reveals new, high-value drug targets
6. Superpowered Bacteria May Lurk Behind Sinus Infections
7. Feces-Linked Bacteria Found at Lake Erie Beaches
8. Could Bacteria in Skin Mites Help Cause Rosacea?
9. New antibacterial coating for sutures could reduce infections after surgery
10. Trudeau researchers identify unforeseen regulation of the anti-bacterial immune response
11. Microbiology and Genome Experts Quell Deadly Bacteria Outbreak
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... CHICAGO, IL (PRWEB) , ... April 24, 2017 , ... Today, Bright Pink , ... cancer in young women, names a new CEO. , Bright Pink is proud to ... announced she would be moving to a new role as Chairman of the Board ...
(Date:4/24/2017)... Boca Raton, Florida (PRWEB) , ... April 24, ... ... that develops a variety of unique liquid food supplements, announced its popular products ... of nutritional products. , ALP Nutrition® prioritizes the use of premium natural ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... (CDC), rising prescription opioid overdose deaths now claim the lives of 62 Americans ... civil case filings against drug manufacturers, distributors, pharmacies and prescribers by more than ...
(Date:4/24/2017)... ... 24, 2017 , ... As a former supermodel known for her timeless beauty, ... for single women is that she put all the words in her new book, ... insight, personal experiences and sparkling sense of humor have inspired her to write a ...
(Date:4/24/2017)... ... April 24, 2017 , ... “Reflections of God’s Work”: an enlightening collection ... Work” is the creation of published author, Jerri Broglin, a survivor of great loss ... believe this a great eye-opener for those searching for answers, as we are finding ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
(Date:4/18/2017)... , April 18, 2017  Cardinal Health (NYSE: ... fiscal 2017 earnings per share (EPS) guidance and ... This is in conjunction with this morning,s announcement of ... Thrombosis and Nutritional Insufficiency businesses. Cardinal Health ... operations will be at the bottom of its previous ...
(Date:4/18/2017)... BLOOMINGTON, Minn. , April 18, 2017 ... ) ("Imprimis"), an ophthalmology-focused pharmaceutical company, and Cameron ... announced the signing of a three-year exclusive sales ... deploy a dedicated sales team to introduce Imprimis, ... primarily focused in 13 states in the U.S. ...
Breaking Medicine Technology: